Clinical Trial

LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a phase III， Multicenter, Randomized study， evaluating the efficacy and Safety of LM-108(an Anti-CCR8 mAb) in combination With Toripalimab Versus Paclitaxel Injection in subjects with CCR8-Positive locally advanced or metastatic Gastric Cancer and Gastroesophageal Junction Adenocarcinoma.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-12
Trial Details
NCT Number NCT07362186
Lead Sponsor LaNova Medicines Limited
Conditions Locally Advanced or Metastatic GC and GCJ Adenocarcinoma
Enrollment 400 participants
Start Date 2026-04-30
Primary Completion 2028-08-17 (estimated)
Study Completion 2028-09-28 (estimated)
Updated on ClinicalTrials.gov 2026-05-11